have developed a revolutionary synthetic approach, which has not only significantly
reduced the total synthetic steps of prostaglandins but has also
efficiently lowered the levels of impurities, particularly stereo-isomers,
in the final products. We have current two patent applications with major
patents offices worldwide (US 2007/0166809 and US 2007/0167641). More
proprietary work has been developed for different product lines and is to
be filed of patents soon. Due to the novel technology platform, we aim to
provide a total solution for prostaglandin synthesis and have been able to
expand the product spectrum and capacity easily, yet have maintained a high
product quality comparable to that of the originators. More excitingly,
hundreds of novel PG intermediates, explored along with the mentioned novel
approaches, offer more possibilities for convenient synthesis of new PG
entities and facilitate the screening of new PG drugs, which may not be
achievable when using conventional approaches.
It should also be noticed that
Chirogate carries the entire synthesis of prostaglandin products by our own
from the very beginning to final products, including every intermediates.
Unlike other manufacturers, which could face problems due to shortage of
key reaction intermediates supplies, Chirogate fully controls the
manufacturing of final products. With independent manufacturing
capabilities, Chirogate assures steady supply of our products and efficient
control of the product prices in conforming with market expectations.